Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01839916 · OUTCOME

Rate of Chronic GVHD (cGVHD)

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · Source last updated 2019-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
At 1 year and 2 year

What was measured

Estimated by cumulative incidence method.

Analysis population: Patients received at least one DLI treatment.

Groups in this outcome

Treatment (DLI)

Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (DLI)36

Reported measurements

At 1 year
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (DLI)26.6Not reported12.243.4Not reported
At 2 year
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (DLI)26.6Not reported12.243.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        12.2
        upper Limit
        43.4
        value
        26.6
    title
    At 1 year
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        12.2
        upper Limit
        43.4
        value
        26.6
    title
    At 2 year
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
Estimated by cumulative incidence method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    Treatment (DLI)
param Type
NUMBER
population Description
Patients received at least one DLI treatment.
reporting Status
POSTED
time Frame
At 1 year and 2 year
title
Rate of Chronic GVHD (cGVHD)
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice